# US 2015/0105419 A1 · Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c}pyridines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105419 A1
- Document ID: US20150105419A1
- Status: Published application
- Kind: A1
- Application number: 14/387,033
- Filed: 2013-03-14
- Published: 2015-04-16
- Earliest claimed: 2012-03-23
- Assignees: Memorial Sloan Kettering Cancer Center; The Rockefeller University
- Applicants: Memorial Sloan-Kettering Cancer Center; The Rockefeller University
- Inventors: Marilyn D. Resh; Joseph Fraser Glickman; Elissaveta Petrova; Ouathek Ouerfelli
- Web page: https://patentgrep.com/patent/US20150105419A1

## CPC

- A61K 31/4365: the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 495/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Methods for inhibiting the growth of pancreatic cancer cells or other cancer cells driven by Sonic hedgehog are disclosed. The method involves exposing the cells to 5-acyl-6,7-dihydrothieno[3,2-c]pyridines of formula (I)

## Claims

### Claim 1

A compound of formula
wherein
R1 and R2 are independently selected from H, halogen, (C1-C4)hydrocarbyl, (C1-C4)alkoxy, trifluoromethyl, trifluoromethoxy, cyano and nitro;
R3 is selected from (C1-C10)hydrocarbyl, (C1-C6)oxaalkyl and heterocyclylalkyl;
R4 is selected from H, methyl, halomethyl, dihalomethyl, and trihalomethyl; and
A is phenyl or a 5- or 6-membered aromatic heterocycle;
with the provisos that,
(a) when R3 is cyclopropyl, R4 is H and A is phenyl, then the combination of R1, R2 and A cannot result in 4-t-butylphenyl, 4-methoxyphenyl, 4-methylphenyl, 2-methylphenyl, 4-chlorophenyl, phenyl, 4-fluorophenyl or 2,4-dichlorophenyl; and
(b) when R3 is cyclohexyl, R4 is H and A is phenyl, then the combination of R1, R2 and A cannot result in 2-methylphenyl or 2,4-dichlorophenyl.

### Claim 2

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula
wherein
R1 and R2 are independently selected from H, halogen, (C1-C4)hydrocarbyl, (C1-C4)alkoxy, trifluoromethyl, trifluoromethoxy, cyano and nitro;
R3 is selected from (C1-C10)hydrocarbyl, (C1-C6)oxaalkyl and heterocyclylalkyl;
R4 is selected from H, methyl, halomethyl, dihalomethyl, and trihalomethyl; and
A is phenyl or a 5- or 6-membered aromatic heterocycle.

### Claim 3 (depends on 1)

A compound or composition according to claim 1 wherein A is chosen from pyrrolidine, furan, thiophene and pyridine.

### Claim 4 (depends on 3)

A compound or composition according to claim 3 wherein R1 is H and R2 is H or methyl.

### Claim 5 (depends on 4)

A compound or composition according to claim 4 wherein A is pyridine.

### Claim 6 (depends on 1)

A compound or composition according to claim 1 wherein A is phenyl.

### Claim 7 (depends on 6)

A compound or composition according to claim 6 wherein R1 is ortho relative to the point of attachment of phenyl to the thieno[3,2-c]pyridine and R2 is para to the point of attachment of phenyl to the thieno[3,2-c]pyridine.

### Claim 8 (depends on 7)

A compound or composition according to claim 7 wherein R1 is H or methyl and R2 is chosen from H, methyl, methoxy, chloro and fluoro.

### Claim 9 (depends on 7)

A compound or composition according to claim 7 wherein R1 and R2 are the same and are chosen from H and halogen.

### Claim 10 (depends on 1)

A compound or composition according to claim 1 wherein R3 is selected from (C1-C10)alkyl, (C1-C6)oxaalkyl and heterocyclylalkyl.

### Claim 11 (depends on 1)

A compound or composition according to claim 1 wherein R3 is chosen from (C3-C6)alkyl, (C3-C6)alkenyl, (C3-C6)cycloalkyl, (C1-C6)oxaalkyl, furanyl(C1-C4)alkyl, thienyl(C1-C4)alkyl, pyrrolyl(C1-C4)alkyl, pyrrolidinyl(C1-C4)alkyl and tetrahydrofuranyl(C1-C4)alkyl.

### Claim 12 (depends on 11)

A compound or composition according to claim 11 wherein R3 is chosen from (C3-C6)alkyl, methoxyethyl, methoxypropyl, ethoxypropyl, isopropyl, cyclopropyl, allyl and furanylmethyl.

### Claim 13 (depends on 1)

A compound or composition according to claim 1 wherein R4 is hydrogen.

### Claim 14 (depends on 1)

A compound or composition according to claim 1 wherein R1 is meta relative to the point of attachment of phenyl to the thieno[3,2-c]pyridine.

### Claim 15 (depends on 14)

A compound or composition according to claim 14 wherein R1 is methyl and R2 is hydrogen.

### Claim 16

A method for treating a patient having an Shh-driven cancer comprising administering to said patient a therapeutically effective amount of a compound of formula
wherein
R1 and R2 are independently selected from H, halogen, (C1-C4)hydrocarbyl, (C1-C4)alkoxy, trifluoromethyl, trifluoromethoxy, cyano and nitro;
R3 is selected from (C1-C10)hydrocarbyl, (C1-C6)oxaalkyl and heterocyclylalkyl;
R4 is selected from H, methyl, halomethyl, dihalomethyl, and trihalomethyl; and
A is phenyl or a 5- or 6-membered aromatic heterocycle.

### Claim 17 (depends on 16)

A method according to claim 16 wherein said cancer is chosen from pancreatic cancer, gastric cancer, colon cancer, prostate cancer, osteosarcoma and small cell lung cancer.

### Claim 18 (depends on 1)

Use of a compound or composition according to claim 1 for the manufacture of a medicament for the treatment of an Shh-driven cancer.

### Claim 19 (depends on 18)

Use according to claim 18 wherein said cancer is chosen from pancreatic cancer, gastric cancer, colon cancer, prostate cancer, osteosarcoma and small cell lung cancer.
